SETD1A and breast carcinoma: Wu et al. (2020) uncovered the role of SETD1A in sorafenib resistance in hepatocellular carcinoma by activating Yes-associates protein (YAP) signalling. Similarly, SETD1A was also linked to tamoxifen resistance in breast cancer by promoting the expression of sex-determining region Y-box 2 SOX2 (Jin et al., 2022).